Patient survival after axillary lymphatic metastasis from breast cancer is generally assessed broadly using a five-year survival rate. With good molecular staging of the pathology and no distant metastasis, the overall five-year survival rate of patients is more than 80%, and most of the patients survive for a longer period of time.
In the case of axillary lymphatic metastasis of breast cancer, the lymph nodes have not fused into clusters and appear as isolated lymph nodes, the molecular typing of the pathology is good, and there is no distant metastasis, it can be judged as stage II, and the five-year survival rate of the patients is about 90%.
In case of axillary lymphatic metastasis of breast cancer, the lymph nodes are fused into clusters and show a fixed form, but the molecular typing of pathology is better and there is no distant metastasis, it can be judged as stage III, and the 5-year survival rate of patients is about 80%.
Therefore, even if breast cancer is accompanied by axillary lymphatic metastasis, it should be treated actively, and the survival period will be significantly prolonged after active treatment. After diagnosed with breast cancer, family members should have more humanistic care, encourage and comfort patients to face the disease with a positive mindset and cooperate with the treatment, so as to control the development of the disease and prolong the survival period.